Search Results - "Gimel, P."

Refine Results
  1. 1
  2. 2
  3. 3

    CCAFU french national guidelines 2016-2018 on renal cancer by Bensalah, K, Albiges, L, Bernhard, J-C, Bigot, P, Bodin, T, Boissier, R, Corréas, J-M, Gimel, P, Long, J-A, Nouhaud, F-X, Ouzaïd, I, Paparel, P, Rioux-Leclercq, N, Méjean, A

    Published in Progrès en urologie (Paris) (01-11-2016)
    “…The previous guidelines from the Cancer Committee of the Association Française d'Urologie were published in 2013. We wanted this new version to be simple,…”
    Get more information
    Journal Article
  4. 4

    Is there a volume–outcome relationship for partial nephrectomy? by Couapel, J.-P., Bensalah, K., Bernhard, J.-C., Pignot, G., Zini, L., Lang, H., Rigaud, J., Salomon, L., Bellec, L., Soulié, M., Vaessen, C., Rouprêt, M., Jung, J.-L., Mourey, E., Bigot, P., Bruyère, F., Berger, J., Ansieau, J.-P., Gimel, P., Salome, F., Hubert, J., Pfister, C., Baumert, H., Timsit, M.-O., Méjean, A., Patard, J. J.

    Published in World journal of urology (01-10-2014)
    “…Objective To investigate the impact of hospital volume on partial nephrectomy indications and outcomes. Materials and methods Data were extracted from the…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Renal cell carcinoma: antiangiogenic therapies and management of the complications. A case report by Fendler, J-P, Malavaud, B, Gimel, P, Duclos, B, Chevreau, C, Pignot, G

    Published in Progrès en urologie (Paris) (01-03-2010)
    “…Direct side effects of the inhibition of activation of VEGF receptors are well known and could be easily explained (HTA). The indirect toxicity of the…”
    Get more information
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Case report of kidney cancer from JOUM 2010 by Neuzillet, Y, Guy, L, Long, J-A, Zini, L, Chevreau, C, Duclos, B, Escudier, B, Gimel, P, Joly, F, Lang, H, Mejean, A, Oudard, S, Roumeguere, T

    Published in Progrès en urologie (Paris) (01-03-2011)
    “…Three clinical cases have shown the superiority of sunitinib in first line therapy intermediate risk metastatic clear cell renal carcinoma and a best safety of…”
    Get more information
    Journal Article
  18. 18
  19. 19
  20. 20